表紙
市場調査レポート

非アルコール性脂肪肝疾患 (NAFLD):世界の治験動向

Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015

発行 GlobalData 商品コード 325403
出版日 ページ情報 英文 197 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
非アルコール性脂肪肝疾患 (NAFLD):世界の治験動向 Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015
出版日: 2015年12月16日 ページ情報: 英文 197 Pages
概要

当レポートでは、非アルコール性脂肪肝疾患 (NAFLD)に関する臨床研究の最新動向について調査し、地域・進捗状況・フェーズ (相) ・募集状況別の実施件数や、代表的なスポンサー、開発中の治療薬の情報、世界各国の主要企業・機関での進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

イントロダクション

  • 非アルコール性脂肪肝疾患 (NAFLD)
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:消化器系疾患治療薬の治験における非アルコール性脂肪肝疾患 (NAFLD)の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:消化器系疾患治療薬の治験における非アルコール性脂肪肝疾患 (NAFLD)の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

非アルコール性脂肪肝疾患 (NAFLD)治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 主要企業の治験の概要
    • Galmed International Ltd.
    • AstraZeneca PLC
    • TCM Biotech International Corp
    • Phenex Pharmaceuticals AG
    • PharmaKing Co., Ltd.
    • Genextra S.p.a.
    • F. Hoffmann-La Roche Ltd.
    • Barij essence Company
    • Antipodean Pharmaceuticals, Inc.
    • Abbott Laboratories
  • 代表的な研究機関・病院の治験の概要
    • Tabriz University of Medical Sciences
    • Third Military Medical University
    • Tehran University of Medical Sciences
    • University of Michigan
    • The National Institute of Diabetes and Digestive and Kidney Diseases
    • FUDAN University
    • Massachusetts General Hospital
    • Chinese University of Hong Kong
    • Ahvaz Jundishapur University of Medical Sciences
    • Bambino Gesu Hospital and Research Institute

5つの代表的な治験のプロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3082CTIDB

GlobalData's clinical trial report, "Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H2, 2015" provides an overview of Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials scenario. This report provides top line data relating to the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Non Alcoholic Fatty Liver Disease (NAFLD)
      • Nov 16, 2015: NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD
      • Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015*
  • Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*

List of Figures

  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015*
  • Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Back to Top